- The FDA has granted Breakthrough Therapy Designation to Takeda Pharmaceutical Company Limited's TAK TAK-994 for excessive daytime sleepiness (EDS) in patients with narcolepsy type 1 (NT1).
- The oral orexin agonist is currently in Phase 2 study.
- EDS is a hallmark symptom of NT1 and is characterized by a person's inability to stay awake and alert throughout the day and falling asleep unintentionally or at inappropriate times.
- Price Action: TAK shares are up 1.34% at $16.99 during the market session on the last check Wednesday.
- Related content: Benzinga's Full FDA Calendar.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
